Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review.

ABSTRACT:

Importance

Molecular techniques, including next-generation sequencing, genomic copy number profiling, fusion transcript detection, and genomic DNA methylation arrays, are now indispensable tools for the workup of central nervous system (CNS) tumors. Yet there remains a great deal of heterogeneity in using such biomarker testing across institutions and hospital systems. This is in large part because there is a persistent reluctance among third-party payers to cover molecular testing. The objective of this Review is to describe why comprehensive molecular biomarker testing is now required for the accurate diagnosis and grading and prognostication of CNS tumors and, in so doing, to justify more widespread use by clinicians and coverage by third-party payers.

Observations

The 5t

SUBMITTER: Horbinski C 

PROVIDER: S-EPMC12344474 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature